article thumbnail

ASCO 2024 Round Up: Advancements in Biomarker-Driven Medicines, Cancer Vaccines, and AI Applications Paving the Way for Expansion of Precision Oncology

Frost & Sullivan

Antibody-Drug Conjugate (ADC) Targets: Current and Future Targets Remains a Priority Focus Big biopharma has embraced the trend of transitioning primary cancer treatment from chemotherapy to innovative targeted treatments since the ADC market is projected to grow at a CAGR of 25.4%